Montréal’s DropGenie raises US$5 million to commercialize a gene-editing chip

The company says its chip can use up to 100 times fewer cells and less reagent than traditional tests; BetaKit’s report provides no independent comparison of those claimed savings.
Operators evaluating the workflow should compare its cell and reagent requirements with experimental results before relying on the claimed savings in their own labs.